Study on UBE2G1: Potential Drug Target Or Biomarker for Various Diseases

Target Name: UBE2G1

NCBI ID: G7326

UBE2G1

Study on UBE2G1: Potential Drug Target Or Biomarker for Various Diseases

UBE2G1 (UBE2G1_HUMAN), a gene located on chromosome 6, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions and interactions with other genes have been extensively studied, providing a foundation for its potential use in drug development.

UBE2G1 is a non-coding RNA molecule that plays a role in the regulation of gene expression. It is composed of 291 amino acid residues and has a calculated molecular weight of 31 kDa. UBE2G1 is predominantly expressed in the brain and nervous tissue, with lower levels found in other tissues. Its expression is regulated by post-transcriptional modification (RNA modification), such as RNA-binding protein (RBP) binding and phosphorylation modification.

UBE2G1 has been shown to play a role in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It has also been associated with cancer, with higher expression levels observed in tissues of patients with various types of cancer.

One of the most significant functions of UBE2G1 is its role in the regulation of dopamine (neurotransmitter) signaling. Dopamine is a neurotransmitter that plays a crucial role in the transmission of signals in the brain, and is involved in various brain functions, including motivation, pleasure, and movement control. UBE2G1 has been shown to regulate the expression of genes involved in dopamine signaling, including the dopamine receptor, the dopamine transporter, and the cAMP-protein kinase (PLC) kinase.

In addition, UBE2G1 is also involved in the apoptosis (apoptosis) process of neurons. Neuronal apoptosis is an important way of cell death and plays a key role in the growth, regeneration and repair of neurons. Studies have shown that the expression level of UBE2G1 is positively correlated with the apoptosis rate of neurons, and its reduced expression may be a potential cause of excessive or insufficient neuronal apoptosis.

In addition, UBE2G1 is also involved in immune cell functions, including the activation of T cells and macrophages. Studies have shown that UBE2G1 can regulate a variety of immune molecules in immune cells, such as TLR (peripheral molecules that recognize bacteria and viruses) and PD-1 (PD-1 receptor on T cells). These immune cells play an important role in immune responses and diseases. Therefore, the role of UBE2G1 in immune regulation has also attracted attention.

In addition, UBE2G1 is also related to a variety of diseases and drug targets. Such as genes related to neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, and genes related to tumors, such as liver cancer and breast cancer. Therefore, studying UBE2G1 as a drug target or biomarker has broad application prospects in drug development and disease treatment.

Although no drugs targeting UBE2G1 have yet entered clinical treatment, research on UBE2G1 is still actively underway. For example, researchers are exploring UBE2G1 as a potential antipsychotic drug target to study its antipsychotic effects. In addition, researchers are also studying UBE2G1 as a potential anti-neurodegenerative drug target and studying its role in fighting neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.

With the continuous advancement of technology, the research on UBE2G1 will also be more in-depth. Researchers will continue to explore the potential of UBE2G1 in the field of drug targets or biomarkers, and strive to develop more effective drugs to bring hope for the treatment of diseases.

Protein Name: Ubiquitin Conjugating Enzyme E2 G1

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-, as well as 'Lys-63'-linked polyubiquitination. May be involved in degradation of muscle-specific proteins. Mediates polyubiquitination of CYP3A4

The "UBE2G1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2G1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets